Blog
Welcome to the Gateway Analytical Blog section of our website. In here we post information on the latest emerging technologies, articles or posts from our scientists, our quality corner with advice on QA/QC for laboratories and much more.
Presumptive Testing of Biological Fluids
The evaluation of forensic evidence has changed significantly since the 1994 DNA Identification Act. Forensic DNA analysis plays a critical role in criminal investigations, and as a result now presents forensic labs with huge backlog issues due to the number of samples submitted for examination. This is where presumptive testing of evidence, such as suspected [...]
Gateway Analytical to Present at 2012 MAAFS Meeting: The Introduction of Hyperspectral Imaging as an Additional Method of Examination for Tapes
The Mid-Atlantic Association of Forensic Scientists (MAAFS) annual meeting is being held later this month from May 14th through the 18th. MAAFS is one of several regional/state forensic science associations in the United States. Regional meetings are great for scientists to attend because they usually require less travel than attending the national AAFS meeting, and [...]
Preview: Joint Poster at Respiratory Drug Delivery 2012
This year at Respiratory Drug Delivery 2012, Dr. Oksana Olkhovyk will be presenting a poster with Christopher Vernall from the University of Bath which is located in the UK. This year’s poster topic, titled: “Investigation of the Microstructure of Combination Dry Powder Inhaler Formulations by Atomic Force Microscopy and Raman Chemical Imaging”, aims to investigate [...]
Webinar Recap: Laboratory Methods for the Examination of Foreign Particulate Matter
On April 25th, 2012 we hosted a live webinar titled “Laboratory Methods for the Examination of Foreign Particulate Matter.” During the webinar our presenters, David Exline, Senior V.P. and Antonio Scatena, Scientist at Gateway Analytical, discussed current methods of particulate isolation, laboratory testing methods for identifying foreign particulates and the company’s forensic approach to source determination. [...]
Helping Generic Manufacturers Prove Bioequivalence of Suspension Nasal Sprays
In 2004, the FDA launched the Critical Path Initiative as a national strategy to drive innovation in development, evaluation and manufacturing of medical products1. As part of this initiative, the FDA identified a number of Critical Path Opportunities (CPOs) for generic drugs. Namely the CPO for Bioequivalence of Nasal Sprays, which identifies a need for [...]
